Soligenix, Inc. SNGX 深 沪
已收盘 02-06 16:00:00 美东时间
1.13
+0.090
+8.65%
华盛通- 最 高1.16
- 今 开1.05
- 成交量 14.96万股
- 最 低 1.045
- 昨 收 1.04
- 总市值 1139.73万
- 52周最高 6.2299
- 市盈率 静 --
- 换手率 1.48%
- 52周最低 1.02
- 委 比 28.46%
- 总股本 1008.61万
- 历史最高 1219.20
- 量 比 0.68
- 振 幅 11.06%
- 历史最低 1.02
- 每 手 1
- 风险率 0.60%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Soligenix Enters $3.45M At-The-Market Equity Sales Agreement With Rodman & Renshaw
Item 8.01.Other Events. On January 23, 2026, Soligenix, Inc. (the "Company") and Rodman & Renshaw, LLC ("Rodman") entered into an At Market Issuance Sales Agreement (as amended, the "Sales Agreement"),
01-24 05:11
Soligenix Announced Extended Results Of Its Ongoing Phase 2a Trial Of SGX302 (Synthetic Hypericin) For Mild-to-moderate Psoriasis
The Cohort 3 patients were treated for the same 18-week period as Cohorts 1 and 2, but utilized an optimized gel formulation of synthetic hypericin. The gel formulation was specifically designed to improve ease of
2025-12-17 20:34
Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space
Soligenix Inc. (NASDAQ: SNGX), a late-stage biopharmaceutical company, has been featured in an editorial by BioMedWire (BMW) highlighting its efforts in developing treatments for chronic rare diseases, particularly in an aging population. The company is advancing HyBryte™, a synthetic hypericin-based photodynamic therapy for cutaneous T-cell lymphoma (CTCL), with a final confirmatory clinical study underway before seeking global marketing approva...
2025-12-03 13:30
Soligenix Completes Planned Enrollment Of 50 Patients Necessary For Interim Analysis In 80 Patient Confirmatory Phase 3 Double-Blind, Placebo-Controlled Study Evaluating HyBryte In CTCL Treatment
50 of 80 patients enrolled in FLASH2 study Blinded Response Rate to Date Exceeds Trial EstimatePRINCETON, N.J., Nov. 19, 2025 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a
2025-11-19 20:33
Soligenix Q3 EPS $(0.58) Misses $(0.56) Estimate
Soligenix (NASDAQ:SNGX) reported quarterly losses of $(0.58) per share which missed the analyst consensus estimate of $(0.56) by 4.5 percent. This is a 25.64 percent increase over losses of $(0.78) per share from the
2025-11-07 20:40
Soligenix Updates U.S. Medical Advisory Board To Guide Phase 3 HyBryte Development For CTCL
Providing Strategic Medical Guidance in Advancing HyBryte™ Clinical DevelopmentPRINCETON, N.J., Oct. 14, 2025 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage
2025-10-14 19:33
Soligenix Reports No Safety Concerns In First DMC Review Of Phase 3 HyBryte Trial For CTCL
FLASH2 Study Interim Efficacy Analysis Targeted for 1H2026Enrollment Update Remains on Track for 4Q2025PRINCETON, N.J., Oct. 7, 2025 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage
2025-10-07 19:33
快讯 | Soligenix Inc - 于9月25日，与投资者签订证券购买协议 - SEC备案
Soligenix Inc - on Sept 25, Enters Securities Purchase Agreement With Investors...
2025-09-30 04:26
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers bioAffinity Technologies (NASDAQ: BIAF) stock increased by 71.8% to $5.86 during Friday's pre-market session. The company's market cap stands at $4.5 million.
2025-09-26 20:10
Soligenix Announces Pricing of $7.5 Million Public Offering
PRINCETON, N.J., Sept. 26, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) ("Soligenix" or the "Company"), a late-stage biopharmaceutical company focused on developing and commercializin...
2025-09-26 18:33
